Accueil   Diary - News   All news VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE

This partnership concerns the development and commercialization of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits on prediabetics

 

 

  • Nestlé Health Science’s global reach and metabolic diseases focus expected to support TOTUM-63 development and global commercialization;
  • Strategic partnership secures funding for the latest clinical development phase until the obtention of health claims from American and European Authorities;
  • Deal is structured around an upfront payment of CHF 5 million, development & sales milestone payments up to a maximum of CHF 66 million and tiered royalties on net sales;
  • Agreement also includes TOTUM-63 supply to Nestlé Health Science representing an additional source of revenue.

 

 

La Rochelle, 5 February 2020 (5:40 PM CET) – VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the signature of a global long-term strategic partnership with Nestlé Health Science for the development and commercialization of TOTUM-63, an innovative and patented combination of 5 plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetics.

 

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree